CAR T-cell therapy (MaxCyte)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug NameCAR T-cell therapy (MaxCyte)

Drug Alias Namechimeric antigen receptor modified T cells (MaxCyte)

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunostimulantsT lymphocytes stimulants

TargetsUpdating

Therapy Area/IndicationsSolid tumoursOvarian Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesMaxcyte Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMaxcyte Inc

Active IndicationsN/A

Inactive IndicationsSolid tumoursOvarian Neoplasms

Other Information

ATC CodeN/A